We use cookies to ensure that we give you the best experience on our website Learn more

Dec 5, 2017

International Diabetes Federation 2017 Congress

HD-6277, a novel GPR40 agonist improved glycemic control and GLP-1 secretion in rodent models of insulin resistance

;

Kim, C.H.;

Kim, Y.S.;

Choi, H.S.;

Yang, G.;

Kang, S.J.;

Lee, S.H.;

Kim, D.Y.;

Yoo, H.E.;

Yang, J.;

Rhee, J.K.;

Kim, D.H.

gpr40 agonist

hd-6277

glp-1

insulin

Abstract

Abstract

thumbnail

Keywords

gpr40 agonist

hd-6277

glp-1

insulin

Abstract

Background Free fatty acid receptor 1/G protein-coupled receptor 40 (FFA1/GPR40), is predominantly expressed in pancreatic beta cells and has drawn considerable interest as a potential therapeutic target for T2DM due to its important role in enhancing glucose-stimulated insulin secretion (GSIS). GPR40 is also proven to be highly expressed in GLP-1-producing entero endocrine cells afterwards, which opens a potential role of GPR40 in enhancing GLP-1 secretion to exert additional anti-diabetic efficacy. Aim HD-6277 is one such novel oral agonist of GPR40 under development as a once-a-day drug for the treatment of T2DM. Here, we studied the pharmacological effect of HD-6277 and compared the glucose-lowering effects with TAK-875(Fasiglifam), a selective FFA1/GPR40 agonist terminated in phase III clinical trials. Additionally, we compared the pharmacological potency between HD-6277, TAK-875, and LY2922470. Method hGPR40-CHO, INS-1, and NCI-H716 cell lines were used to assess the effects of HD-6277 in vitro. The in vivo effect of HD-6277 was examined in SD rats, Zucker Diabetic Fatty (ZDF) rats and Zucker rats, using an OGTT and an ITT. We also measured the GLP-1 levels on cynomolgus monkeys. Results HD-6277 showed more effective in vitro profile than TAK-875 in calcium influx assay (EC50 = 13 nM) and IP accumulation assay (EC50 = 7.5 nM). In comparison of pharmacological effects between HD-6277, TAK-875 and LY2922470, HD-6277 enhanced GSIS in INS-1 cells and SD rats. In fasted SD rats, while glibenclamide (10 mg/kg) induced hypoglycemia, HD-6277 (10-100 mg/kg) neither caused hypoglycemia nor enhanced insulin secretion. HD-6277 increased GLP-1 secretion in in vitro and in vivo, whereas TAK-875 did not. Then we evaluated the efficacy of HD-6277 (1-10 mg/kg) in rodent models of insulin resistance and type 2 diabetes. In subchronic study with male ZDF rats, HD-6277 improved glycemic control (OGTT) and GLP-1 secretion, and decreased fasting insulin levels. In male Zucker rats, an oral administrations for 10~11 weeks, HD-6277 improved insulin sensitivity (ITT) and HbA1c levels. The impaired insulin action was recovered by HD-6277 treatment in adipose tissue from the Zucker rats. In the cynomolgus monkey study, HD-6277 also showed a significant increase in GLP-1 secretion (P<0.05). Discussion The pharmacological efficacy of HD-6277 was higher than that of TAK-875 and similar to LY2922470. HD-6277 improved glycemic control in type 2 diabetic rats, which may be related to enhancement of insulin signaling and GLP-1 secretion. Therefore, we recommend HD-6277 as an effective candidate for the treatment of T2DM.

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.